FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Oyvind Bruland

Research Profile

Disorders

Chemicals & Drugs

Living Beings

Concepts & Ideas

Objects

Alpha Particles

Anatomy

Tumor Cells, Cultured

Procedures

Geographic Areas

Norway

Co-author Network

Publications

TOP 3
Sten Nilsson; Charles Gillies O'Bryan-Tear; Christopher Parker; Ulf Petersson; Katharine Pigott; Michael Sokal; Jan Tennvall; Marcus Thuresson; Christopher Tyrrell; René Blom; Bjørg Bolstad; Lars Franzén; Dag Clement Johannessen; Bo Lennernäs; Oyvind S Bruland
Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and bone metastases.
Oliver Sartor; Peter Hoskin; Oyvind S Bruland
Targeted radio-nuclide therapy of skeletal metastases.
Jostein Dahle; Arne Kolstad; Katrine B Melhus; Camilla S Mollatt; Ada H V Repetto-Llamazares; Oyvind S Bruland; Roy H Larsen
Evaluating antigen targeting and anti-tumor activity of a new anti-CD37 radioimmunoconjugate against non-Hodgkin's lymphoma.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Oyvind Bruland (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Sten Nilsson; Charles Gillies O'Bryan-Tear; Christopher Parker; Ulf Petersson; Katharine Pigott; Michael Sokal; Jan Tennvall; Marcus Thuresson; Christopher Tyrrell; René Blom; Bjørg Bolstad; Lars Franzén; Dag Clement Johannessen; Bo Lennernäs; Oyvind S Bruland
Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and bone metastases.
Clinical genitourinary cancer 2013;11(1):20-6.
2013: Oliver Sartor; Peter Hoskin; Oyvind S Bruland
Targeted radio-nuclide therapy of skeletal metastases.
Cancer treatment reviews 2013;39(1):18-26.
2013: Jostein Dahle; Arne Kolstad; Katrine B Melhus; Camilla S Mollatt; Ada H V Repetto-Llamazares; Oyvind S Bruland; Roy H Larsen
Evaluating antigen targeting and anti-tumor activity of a new anti-CD37 radioimmunoconjugate against non-Hodgkin's lymphoma.
Anticancer research 2013;33(1):85-95.
2012: Emanuela Micu; Zivile Baturaite; Asta Juzeniene; Oyvind S Bruland; Johan E Moan
Superficial-spreading and nodular melanomas in Norway: a comparison by body site distribution and latitude gradients.
Melanoma research 2012;22(6):460-5.
2012: S Nilsson; P Olivier; A Pecking; J Staffurth; P Strang; S Vasanthan; A K Aksnes; C Andersson; L Franzèn; Oyvind S Bruland
A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer.
European journal of cancer (Oxford, England : 1990) 2012;48(5):678-86.
2012: Heidi Maria Namløs; Gunnar Saeter; Vidar M Steen; Bodil Bjerkehagen; Oyvind S Bruland; Jørn Henriksen; Rita Holdhus; Stine H Kresse; Christoph R Müller; Ola Myklebost
Global gene expression profiling of human osteosarcomas reveals metastasis-associated chemokine pattern.
Sarcoma 2012;2012():639038.
2011: Nina L Jebsen; Clement S Trovik; Ingela Turesson; Oyvind S Bruland; Jacob Engellau; Mikael Eriksson; Annika Folin; Kirsten Sundby Hall
Five-year results from a Scandinavian sarcoma group study (SSG XIII) of adjuvant chemotherapy combined with accelerated radiotherapy in high-risk soft tissue sarcoma of extremities and trunk wall.
International journal of radiation oncology, biology, physics 2011;81(5):1359-66.
2011: Kristin P Anfinsen; Freddie Bray; Oyvind S Bruland; Susan S Devesa; Thora Johanna Jonasdottir; Rebecca Troisi; Tom Grotmol
Age-period-cohort analysis of primary bone cancer incidence rates in the United States (1976-2005).
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2011;20(8):1770-7.
2011: Olga Zaikova; Sophie D Fosså; Oyvind S Bruland; Karl-Erik Giercksky; Berit Sandstad; S Skjeldal
Radiotherapy or surgery for spine metastases?
Acta orthopaedica 2011;82(3):365-71.
2011: Sigbjørn Smeland; Oyvind S Bruland; Lars Hjorth; Otte Brosjö; Bodil Bjerkehagen; Gustaf Osterlundh; Ake Jakobson; Kirsten Sundby Hall; OR Monge; O Björk; Thor A Alvegaard
Results of the Scandinavian Sarcoma Group XIV protocol for classical osteosarcoma: 63 patients with a minimum follow-up of 4 years.
Acta orthopaedica 2011;82(2):211-6.
2011: Dipak Sapkota; Oyvind S Bruland; Daniela Elena Costea; Hallvard Haugen; Endre N Vasstrand; Salah O Ibrahim
S100A14 regulates the invasive potential of oral squamous cell carcinoma derived cell-lines in vitro by modulating expression of matrix metalloproteinases, MMP1 and MMP9.
European journal of cancer (Oxford, England : 1990) 2011;47(4):600-10.
2009: Tonje Anette Sande; Randi Ruenes; Jo Asmund Lund; Oyvind S Bruland; Kjersti Hornslien; Roy Bremnes; Stein Kaasa
Long-term follow-up of cancer patients receiving radiotherapy for bone metastases: results from a randomised multicentre trial.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2009;91(2):261-6.
2009: Petter Brandal; Bodil Bjerkehagen; Oyvind S Bruland; S Skjeldal; Trond V Bogsrud; Kirsten Sundby Hall
Synchronous and metachronous skeletal osteosarcomas: the Norwegian Radium Hospital experience.
Acta oncologica (Stockholm, Sweden) 2009;48(8):1165-72.
2008: Jostein Dahle; Oyvind S Bruland; Roy H Larsen
Relative biologic effects of low-dose-rate alpha-emitting 227Th-rituximab and beta-emitting 90Y-tiuexetan-ibritumomab versus external beam X-radiation.
International journal of radiation oncology, biology, physics 2008;72(1):186-92.
2008: Nina L Jebsen; Clement S Trovik; Henrik C F Bauer; Anders Rydholm; Odd R Monge; Kirsten Sundby Hall; Thor Alvegård; Oyvind S Bruland
Radiotherapy to improve local control regardless of surgical margin and malignancy grade in extremity and trunk wall soft tissue sarcoma: a Scandinavian sarcoma group study.
International journal of radiation oncology, biology, physics 2008;71(4):1196-203.
2008: Alina Carmen Porojnicu; Oyvind S Bruland; Lage Aksnes; William B Grant; Johan Moan
Sun beds and cod liver oil as vitamin D sources.
Journal of photochemistry and photobiology. B, Biology 2008;91(2-3):125-31.
2007: Arne Berg; Wolfgang Lilleby; Oyvind S Bruland; Sophie D Fosså
10-year survival and quality of life in patients with high-risk pN0 prostate cancer following definitive radiotherapy.
International journal of radiation oncology, biology, physics 2007;69(4):1074-83.
2007: Aste Søvik; Eirik Malinen; Hege K Skogmo; Søren M Bentzen; Oyvind S Bruland; Dag Rune Olsen
Radiotherapy adapted to spatial and temporal variability in tumor hypoxia.
International journal of radiation oncology, biology, physics 2007;68(5):1496-504.
2007: Sten Nilsson; Lars Franzén; Christopher Parker; Christopher Tyrrell; René Blom; Jan Tennvall; Bo Lennernäs; Ulf Petersson; Dag Clement Johannessen; Michael Sokal; Katharine Pigott; Jeffrey Yachnin; Michael Garkavij; Peter Strang; Johan Harmenberg; Bjørg Bolstad; Oyvind S Bruland
Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study.
The lancet oncology 2007;8(7):587-94.
2007: Roy H Larsen; Jorgen Borrebaek; Jostein Dahle; Katrine B Melhus; Cecilie Krogh; Miriam H Valan; Oyvind S Bruland
Preparation of TH227-labeled radioimmunoconjugates, assessment of serum stability and antigen binding ability.
Cancer biotherapy & radiopharmaceuticals 2007;22(3):431-7.
2007: Dag Rune Olsen; Oyvind S Bruland; Gunilla Frykholm; Inger Norderhaug
Proton therapy - a systematic review of clinical effectiveness.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2007;83(2):123-32.
2007: Alina Carmen Porojnicu; Trude Eid Robsahm; Arne Dahlback; Jens Berg; David C Christiani; Oyvind S Bruland; Johan Moan
Seasonal and geographical variations in lung cancer prognosis in Norway. Does Vitamin D from the sun play a role?
Lung cancer (Amsterdam, Netherlands) 2007;55(3):263-70.
2006: Allan Lipton; James R Berenson; Jean-Jacques Body; Brendan F Boyce; Oyvind S Bruland; Michael A Carducci; Charles S Cleeland; Denis R Clohisy; Robert E Coleman; Richard J Cook; Theresa A Guise; Roger N Pearse; Trevor J Powles; Michael J Rogers; David G Roodman; Matthew R Smith; Larry J Suva; Robert L Vessella; Katherine N Weilbaecher; Laura King
Advances in treating metastatic bone cancer: summary statement for the First Cambridge Conference.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(20 Pt 2):6209s-6212s.
2006: Thora Johanna Jonasdottir; Darrell R Fisher; Jorgen Borrebaek; Oyvind S Bruland; Roy H Larsen
First in vivo evaluation of liposome-encapsulated 223Ra as a potential alpha-particle-emitting cancer therapeutic agent.
Anticancer research 2006;26(4B):2841-8.
2006: Roy H Larsen; Henrik Saxtorph; Mikala Skydsgaard; Jorgen Borrebaek; Thora Johanna Jonasdottir; Oyvind S Bruland; Signe Klastrup; Robert Harling; Thomas Ramdahl
Radiotoxicity of the alpha-emitting bone-seeker 223Ra injected intravenously into mice: histology, clinical chemistry and hematology.
In vivo (Athens, Greece) 2006;20(3):325-31.
2006: Jostein Dahle; Jorgen Borrebaek; Katrine B Melhus; Oyvind S Bruland; Gro Salberg; Dag Rune Olsen; Roy H Larsen
Initial evaluation of (227)Th-p-benzyl-DOTA-rituximab for low-dose rate alpha-particle radioimmunotherapy.
Nuclear medicine and biology 2006;33(2):271-9.
2006: Liv Hege Aksnes; Kirsten Sundby Hall; Gunnar Folleraas; Anna E Stenwig; Bodil Bjerkehagen; Ingeborg Taksdal; Mette Winderen; Oyvind S Bruland; Gunnar Saeter
Management of high-grade bone sarcomas over two decades: the Norwegian Radium Hospital experience.
Acta oncologica (Stockholm, Sweden) 2006;45(1):38-46.
2005: Oyvind S Bruland; Hanne K Høifødt; Gunnar Saeter; Sigbjørn Smeland; Oystein Fodstad
Hematogenous micrometastases in osteosarcoma patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(13):4666-73.
2005: Sten Nilsson; Roy H Larsen; Sophie D Fosså; Lise Balteskard; Kari W Borch; Jan-Erik Westlin; Gro Salberg; Oyvind S Bruland
First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(12):4451-9.
2005: Odd T Brustugun; Wenche Reed; Jan Peter Poulsen; Oyvind S Bruland
Primary osteosarcoma of the breast.
Acta oncologica (Stockholm, Sweden) 2005;44(7):767-70.
2005: Gjermund Henriksen; Oyvind S Bruland; Roy H Larsen
Preparation and preclinical assessment of folate-conjugated, radiolabelled antibodies.
Anticancer research 2005;25(1A):9-15.
2004: Skjalg Bruheim; Oyvind S Bruland; Knut Breistol; Gunhild M Maelandsmo; Oystein Fodstad
Human osteosarcoma xenografts and their sensitivity to chemotherapy.
Pathology oncology research : POR 2004;10(3):133-41.
2004: Gjermund Henriksen; Oyvind S Bruland; Roy H Larsen
Thorium and actinium polyphosphonate compounds as bone-seeking alpha particle-emitting agents.
Anticancer research 2004;24(1):101-5.
2003: Ole K Olstad; Vigdis T Gautvik; Sjur Reppe; Edith Rian; Rune Jemtland; Claes Ohlsson; Oyvind S Bruland; Kaare M Gautvik
Molecular heterogeneity in human osteosarcoma demonstrated by enriched mRNAs isolated by directional tag PCR subtraction cloning.
Anticancer research 2003;23(3B):2201-16.
2002: Anne Hansen Ree; Ase Bratland; Roger Kroes; Hans-Christian Aasheim; Vivi Ann Flørenes; Joseph R Moskal; Oystein Fodstad; Oyvind S Bruland; Gunhild M Maelandsmo
Clinical and cell line specific expression profiles of a human gene identified in experimental central nervous system metastases.
Anticancer research 2002;22(4):1949-57.
2002: Yngve Kvinnsland; Oyvind S Bruland; Lars Moe; Arne Skretting
A method for measurement of the uptake patterns of two beta-emitting radionuclides in the same tissue section with a digital silicon detector: application to a study of 89SrCl2 and 153Sm-EDTMP in a dog with spontaneous osteosarcoma.
European journal of nuclear medicine and molecular imaging 2002;29(2):191-7.
2002: Peter M Anderson; Gregory A Wiseman; Angela Dispenzieri; Carola A S Arndt; Lynn C Hartmann; William A Smithson; Brian P Mullan; Oyvind S Bruland
High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(1):189-96.
2001: Yngve Kvinnsland; Arne Skretting; Oyvind S Bruland
Radionuclide therapy with bone-seeking compounds: Monte Carlo calculations of dose-volume histograms for bone marrow in trabecular bone.
Physics in medicine and biology 2001;46(4):1149-61.
2000: Ellen Aurlien; Roy H Larsen; Gunnar Kvalheim; Oyvind S Bruland
Demonstration of highly specific toxicity of the alpha-emitting radioimmunoconjugate(211)At-rituximab against non-Hodgkin's lymphoma cells.
British journal of cancer 2000;83(10):1375-9.
2000: S Olberg; Arne Skretting; Oyvind S Bruland; Dag Rune Olsen
Dose distribution measurements by MRI of a phantom containing lung tissue equivalent compartments made of ferrous sulphate gel.
Physics in medicine and biology 2000;45(10):2761-70.
2000: A Pihl; Oyvind S Bruland
Oral presentations in science and medicine. An art in decline?
Anticancer research 2000;20(5A):2795-9.
2000: Ellen Aurlien; Roy H Larsen; Gamal Akabani; Dag Rune Olsen; M R Zalutsky; Oyvind S Bruland
Exposure of human osteosarcoma and bone marrow cells to tumour-targeted alpha-particles and gamma-irradiation: analysis of cell survival and microdosimetry.
International journal of radiation biology 2000;76(8):1129-41.
1999: KM Murud; Roy H Larsen; Oyvind S Bruland; Per Hoff
Influence of pretreatment with 3-amino-1-hydroxypropylidene-1,1-bisphosphonate (APB) on organ uptake of 211At and 125I-labeled amidobisphosphonates in mice.
Nuclear medicine and biology 1999;26(7):791-4.
1999: Magne Aas; Lars Moe; H Gamlem; Arne Skretting; N Ottesen; Oyvind S Bruland
Internal radionuclide therapy of primary osteosarcoma in dogs, using 153Sm-ethylene-diamino-tetramethylene-phosphonate (EDTMP).
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(10 Suppl):3148s-3152s.
1999: Anne Hansen Ree; M Tvermyr; Olav Engebraaten; M Rooman; Oystein Røsok; Eivind Hovig; Leonardo A. Meza-Zepeda; Oyvind S Bruland; Oystein Fodstad
Expression of a novel factor in human breast cancer cells with metastatic potential.
Cancer research 1999;59(18):4675-80.
1999: Roy H Larsen; KM Murud; Gamal Akabani; Per Hoff; Oyvind S Bruland; M R Zalutsky
211At- and 131I-labeled bisphosphonates with high in vivo stability and bone accumulation.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1999;40(7):1197-203.
1999: Rune Jemtland; Edith Rian; Ole K Olstad; E Haug; Oyvind S Bruland; E Bucht; Kaare M Gautvik
Two human osteoblast-like osteosarcoma cell lines show distinct expression and differential regulation of parathyroid hormone-related protein.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 1999;14(6):904-14.
1998: Roy H Larsen; Oyvind S Bruland
Intratumour injection of immunoglobulins labelled with the alpha-particle emitter 211At: analyses of tumour retention, microdistribution and growth delay.
British journal of cancer 1998;77(7):1115-22.
1998: SP Hassfjell; Arne Skretting; Oyvind S Bruland; Per Hoff
Predicting detectability in radioguided surgery: a study based on physical characterization of the probe and on tissue uptake ratios of 125I-, 153Sm- and 165Er-labelled radiopharmaceuticals.
Nuclear medicine communications 1998;19(3):207-17.
1997: Oyvind S Bruland; A Pihl
On the current management of osteosarcoma. A critical evaluation and a proposal for a modified treatment strategy.
European journal of cancer (Oxford, England : 1990) 1997;33(11):1725-31.
1997: SP Hassfjell; Oyvind S Bruland; Per Hoff
212Bi-DOTMP: an alpha particle emitting bone-seeking agent for targeted radiotherapy.
Nuclear medicine and biology 1997;24(3):231-7.
1997: Per O Ekstrøm; Karl-Erik Giercksky; Anders Andersen; Oyvind S Bruland; L Slørdal
Intratumoral differences in methotrexate levels within human osteosarcoma xenografts studied by microdialysis.
Life sciences 1997;61(19):PL275-80.
1996: Lars Moe; Morten Boysen; Magne Aas; L Lønaas; H Gamlem; Oyvind S Bruland
Maxillectomy and targeted radionuclide therapy with 153Sm-EDTMP in a recurrent canine osteosarcoma.
The Journal of small animal practice 1996;37(5):241-6.
1996: Gunnar Saeter; Oyvind S Bruland; G Follerås; Morten Boysen; J Høie
Extremity and non-extremity high-grade osteosarcoma -- the Norwegian Radium Hospital experience during the modern chemotherapy era.
Acta oncologica (Stockholm, Sweden) 1996;35 Suppl 8():129-34.
1996: Oyvind S Bruland; Arne Skretting; OP Solheim; Magne Aas
Targeted radiotherapy of osteosarcoma using 153 Sm-EDTMP. A new promising approach.
Acta oncologica (Stockholm, Sweden) 1996;35(3):381-4.
1996: T Olafsen; Oyvind S Bruland; Michael R Zalutsky; Inger Sandlie
Abundant tyrosine residues in the antigen binding site in anti-osteosarcoma monoclonal antibodies TP-1 and TP-3: Application to radiolabeling.
Acta oncologica (Stockholm, Sweden) 1996;35(3):297-301.
1995: T Olafsen; Oyvind S Bruland; Michael R Zalutsky; Inger Sandlie
Cloning and sequencing of V genes from anti-osteosarcoma monoclonal antibodies TP-1 and TP-3: location of lysine residues and implications for radiolabeling.
Nuclear medicine and biology 1995;22(6):765-71.
1995: Roy H Larsen; Per Hoff; I B Vergote; Oyvind S Bruland; Magne Aas; L De Vos; Kjell Nustad
Alpha-particle radiotherapy with 211At-labeled monodisperse polymer particles, 211At-labeled IgG proteins, and free 211At in a murine intraperitoneal tumor model.
Gynecologic oncology 1995;57(1):9-15.
1995: Oyvind S Bruland
Cancer therapy with radiolabeled antibodies. An overview.
Acta oncologica (Stockholm, Sweden) 1995;34(8):1085-94.
1994: Roy H Larsen; Oyvind S Bruland; Per Hoff; J Alstad; T Lindmo; E K Rofstad
Inactivation of human osteosarcoma cells in vitro by 211At-TP-3 monoclonal antibody: comparison with astatine-211-labeled bovine serum albumin, free astatine-211 and external-beam X rays.
Radiation research 1994;139(2):178-84.
1994: Roy H Larsen; Oyvind S Bruland; Per Hoff; J Alstad; E K Rofstad
Analysis of the therapeutic gain in the treatment of human osteosarcoma microcolonies in vitro with 211At-labelled monoclonal antibody.
British journal of cancer 1994;69(6):1000-5.
1994: I Kjønniksen; Mette Winderen; Oyvind S Bruland; Oystein Fodstad
Validity and usefulness of human tumor models established by intratibial cell inoculation in nude rats.
Cancer research 1994;54(7):1715-9.
1994: Oyvind S Bruland; Oystein Fodstad; Magne Aas; OP Solheim; J Høie; Arne Skretting; Mette Winderen; T Michaelsen; A Pihl
Immunoscintigraphy of bone sarcomas--results in 5 patients.
European journal of cancer (Oxford, England : 1990) 1994;30A(10):1484-9.
1993: A Andreassen; T Oyjord; Eivind Hovig; Ruth Holm; Vivi Ann Flørenes; Jahn M Nesland; Ola Myklebost; J Høie; Oyvind S Bruland; A L Børresen
p53 abnormalities in different subtypes of human sarcomas.
Cancer research 1993;53(3):468-71.
1992: I Vergote; Roy H Larsen; L de Vos; Jahn M Nesland; Oyvind S Bruland; J Bjørgum; J Alstad; Claes Tropé; Kjell Nustad
Therapeutic efficacy of the alpha-emitter 211At bound on microspheres compared with 90Y and 32P colloids in a murine intraperitoneal tumor model.
Gynecologic oncology 1992;47(3):366-72.
1992: Vivi Ann Flørenes; Steinar Aamdal; Ola Myklebost; Gunhild M Maelandsmo; Oyvind S Bruland; Oystein Fodstad
Levels of nm23 messenger RNA in metastatic malignant melanomas: inverse correlation to disease progression.
Cancer research 1992;52(21):6088-91.
1990: J G Fjeld; Oyvind S Bruland; Haakon B Benestad; L Schjerven; stigbrand torgny; Kjell Nustad
Radioimmunotargeting of human tumour cells in immunocompetent animals.
British journal of cancer 1990;62(4):573-8.
1988: Oyvind S Bruland; Oystein Fodstad; A E Stenwig; A Pihl
Expression and characteristics of a novel human osteosarcoma-associated cell surface antigen.
Cancer research 1988;48(18):5302-9.
1987: Oyvind S Bruland; O Fodstad; Arne Skretting; A Pihl
Selective localisation of two radiolabelled anti-sarcoma monoclonal antibodies in human osteosarcoma xenografts.
British journal of cancer 1987;56(1):21-5.
1986: O Fodstad; A Brøgger; Oyvind S Bruland; OP Solheim; J M Nesland; A Pihl
Characteristics of a cell line established from a patient with multiple osteosarcoma, appearing 13 years after treatment for bilateral retinoblastoma.
International journal of cancer. Journal international du cancer 1986;38(1):33-40.
1986: A Godal; Oyvind S Bruland; E Haug; M Aas; O Fodstad
Unexpected expression of the 250 kD melanoma-associated antigen in human sarcoma cells.
British journal of cancer 1986;53(6):839-41.